[go: up one dir, main page]

BR0112582A - Sulfonamidas de ciclilamina como agonistas de receptores beta-3 adrenérgicos - Google Patents

Sulfonamidas de ciclilamina como agonistas de receptores beta-3 adrenérgicos

Info

Publication number
BR0112582A
BR0112582A BR0112582-6A BR0112582A BR0112582A BR 0112582 A BR0112582 A BR 0112582A BR 0112582 A BR0112582 A BR 0112582A BR 0112582 A BR0112582 A BR 0112582A
Authority
BR
Brazil
Prior art keywords
cyclylamine
beta
sulfonamides
receptor agonists
adrenergic receptor
Prior art date
Application number
BR0112582-6A
Other languages
English (en)
Inventor
Fuk-Wah Sum
Baihua Hu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0112582A publication Critical patent/BR0112582A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fodder In General (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

"SULFONAMIDAS DE CICLILAMINA COMO AGONISTAS DE RECEPTORES BETA-3 ADRENéRGICOS". A presente invenção refere-se a compostos de Fórmula (1), em que R~ 1~, R~ 2~, R~ 3~, W, X e Z são como definidos antes ou um sal farmaceuticamente aceitável disso, os quais são úteis em tratar distúrbios metabólicos relacionados a resistência a insulina ou hiperglicemia.
BR0112582-6A 2000-07-17 2001-07-16 Sulfonamidas de ciclilamina como agonistas de receptores beta-3 adrenérgicos BR0112582A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21876400P 2000-07-17 2000-07-17
PCT/US2001/022359 WO2002006221A2 (en) 2000-07-17 2001-07-16 Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists

Publications (1)

Publication Number Publication Date
BR0112582A true BR0112582A (pt) 2003-05-20

Family

ID=22816416

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112582-6A BR0112582A (pt) 2000-07-17 2001-07-16 Sulfonamidas de ciclilamina como agonistas de receptores beta-3 adrenérgicos

Country Status (10)

Country Link
US (2) US6498170B2 (pt)
EP (1) EP1328512A2 (pt)
JP (1) JP2004504296A (pt)
CN (1) CN1455769A (pt)
AR (1) AR032466A1 (pt)
AU (1) AU2002222929A1 (pt)
BR (1) BR0112582A (pt)
CA (1) CA2416667A1 (pt)
MX (1) MXPA03000450A (pt)
WO (1) WO2002006221A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4334766B2 (ja) * 1998-04-01 2009-09-30 カーディオム ファーマ コーポレイション アミノシクロヘキシルエーテル化合物およびその用途
US6979685B1 (en) * 1999-02-12 2005-12-27 Cardiome Pharma Corp. Cycloalkyl amine compounds and uses thereof
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6410734B1 (en) * 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US7524879B2 (en) * 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7057053B2 (en) * 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US6693099B2 (en) * 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6885903B2 (en) * 2001-07-10 2005-04-26 General Electric Company Method and system for tracking repair of components
US6856733B2 (en) * 2001-12-07 2005-02-15 Intel Corporation 1xN fanout waveguide photodetector
US20090041841A1 (en) * 2003-05-02 2009-02-12 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
SG2010079697A (en) * 2003-05-02 2016-09-29 Cardiome Pharma Corp Aminocyclohexyl ether compounds and uses thereof
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
US7674820B2 (en) * 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
US7345087B2 (en) * 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US8058304B2 (en) * 2004-04-01 2011-11-15 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
MXPA06011419A (es) 2004-04-01 2007-04-20 Cardiome Pharma Corp Profarmacos de compuestos moduladores de canales ionicos y usos de los mismos.
CN1946685A (zh) * 2004-04-29 2007-04-11 默克公司 氮杂环丁烷甘氨酸转运蛋白抑制剂
EP1868598B1 (en) * 2004-11-08 2014-04-23 Cardiome Pharma Corp. A new dosing regimen for ion channel modulating compounds for treating acute atrial fibrillation in a human
US20070054590A1 (en) * 2005-08-24 2007-03-08 Schmidt Christopher B Photo-chromic toys
JP5114202B2 (ja) 2005-09-27 2013-01-09 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するスルホンアミド誘導体
AU2006300877A1 (en) * 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Heterocyclic compounds as pSTAT3/IL-6 inhibitors
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
EP2470021B1 (en) * 2009-08-27 2014-10-22 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
JP6637069B2 (ja) * 2015-01-20 2020-01-29 オロン ソシエタ ペル アチオニＯｌｏｎ Ｓｐａ インダンアミン誘導体の製法及び新規な合成中間体
GB202304661D0 (en) * 2023-03-29 2023-05-10 Atrogi Ab New compounds and medical uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
US4775670A (en) * 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
EP0089154A3 (en) 1982-03-12 1984-08-08 Beecham Group Plc Ethanolamine derivatives, their preparation and use in pharmaceutical compositions
US4499100A (en) * 1983-05-18 1985-02-12 Syntex (U.S.A.) Inc. Benzodioxanyl-hydroxyethyleneamino-piperidinyl acetanilides, ketones, esters and carbamates which effect immunity and calcium entry and β-blockade
GB2163150B (en) 1984-07-19 1988-05-25 Sandoz Ltd 3-aminopropoxyaryl derivatives
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US4813998A (en) 1986-02-27 1989-03-21 Janssen Pharmaceutica N.V. Herbicidal 1H-imidazole-5-carboxylic acid derivatives
EP0449261A3 (en) 1990-03-29 1992-02-26 Kabushiki Kaisha Toshiba Resin composition for an optical disc and an optical disc using it
ATE185564T1 (de) 1992-08-31 1999-10-15 Sankyo Co Oxazolidin-derivate mit antidiabetika und anti- fettleibigkeit-eigenschaften, ihre herstellung und therapeutische verwendung
US5998452A (en) 1993-06-23 1999-12-07 Chugai Seiyaku Kabushiki Kaisha Benzene derivatives, compositions and methods for treating ischemic diseases
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
IL113084A (en) 1994-03-23 1999-01-26 Sankyo Co Thiazolidine and oxazolidine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5614523A (en) 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5789402A (en) 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
CZ126598A3 (cs) * 1995-10-26 1998-09-16 Mitsubishi-Tokyo Pharmaceuticals, Inc. Fenylethanolaminové sloučeniny, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
EP0801060A1 (en) * 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
JP2000511903A (ja) * 1996-06-07 2000-09-12 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のための選択性β▲下３▼作動薬としてのオキサジアゾール・ベンゼンスルホンアミド
AU2995497A (en) 1996-07-26 1997-11-19 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
ES2171839T3 (es) 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
WO1998022480A1 (en) * 1996-11-18 1998-05-28 Smithkline Beecham Plc Phosphorus containing aryloxy or arylthio propanolamine derivatives
WO1998032753A1 (en) * 1997-01-28 1998-07-30 Merck & Co., Inc. THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
US6150378A (en) 1997-10-07 2000-11-21 Cephalon, Inc. Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
AR017340A1 (es) 1997-10-17 2001-09-05 Astellas Pharma Inc Un derivado de amida, su uso y una composicion farmaceutica que lo comprende.
FR2780057B1 (fr) * 1998-06-18 2002-09-13 Sanofi Sa Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
US6214842B1 (en) 1999-05-12 2001-04-10 Michael S. Malamas Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia
FR2798126B1 (fr) 1999-09-08 2001-10-19 Sanofi Synthelabo Heteroaryloxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2001043744A1 (fr) 1999-12-17 2001-06-21 Sanofi-Synthelabo Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2802533B1 (fr) 1999-12-17 2002-02-15 Sanofi Synthelabo Phenoxypropanolamines, leur preparation et leur application en therapeutique
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6458817B1 (en) 2000-07-17 2002-10-01 Wyeth Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6509358B2 (en) 2000-07-17 2003-01-21 Wyeth Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US6514991B2 (en) 2000-07-17 2003-02-04 Wyeth Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists

Also Published As

Publication number Publication date
MXPA03000450A (es) 2003-06-06
US20020022605A1 (en) 2002-02-21
AR032466A1 (es) 2003-11-12
CA2416667A1 (en) 2002-01-24
US20030027797A1 (en) 2003-02-06
JP2004504296A (ja) 2004-02-12
EP1328512A2 (en) 2003-07-23
AU2002222929A1 (en) 2002-01-30
WO2002006221A3 (en) 2002-06-13
WO2002006221A2 (en) 2002-01-24
US6649603B2 (en) 2003-11-18
US6498170B2 (en) 2002-12-24
CN1455769A (zh) 2003-11-12

Similar Documents

Publication Publication Date Title
BR0112582A (pt) Sulfonamidas de ciclilamina como agonistas de receptores beta-3 adrenérgicos
ATE329901T1 (de) 3-substituierte oxindolderivate als beta-3- agonisten
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
BRPI0212894B8 (pt) composto ou sal do mesmo farmaceuticamente aceitável e composição farmacêutica
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
BR0111377A (pt) Derivados de tiofeno úteis como agentes anticancerìgenos
BR0214455A (pt) Derivados benzotiazol
BR0313723A (pt) Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptor
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
ES2173172T3 (es) Derivados de 1,3-dihidroindol-2-ona sustituidos en 3 por un grupo nitrogenado como agonistas y/o antagonistas de la vasopresina y/o de la octocina.
BR0205829A (pt) Novas aminas como ligantes dos receptores de histamina-3 e suas aplicações terapêuticas
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
BR0210538A (pt) Derivados de 5-halotriptamina usados como ligantes dos receptores de serotonina 5-ht6 e/ou 5-ht7
BR0313420A (pt) Quinolonas microbicidas, suas composições e usos
MA31593B1 (fr) Derives de 2-aza-bicyclo[3.3.0]octane
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
BR0112093A (pt) Derivados de sulfonil-pirrolidina úteis no tratamento de distúrbios neurológicos
ATE416157T1 (de) Inhibitoren von integrin alpha-v-beta-6
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
BR0213464A (pt) Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide
AR025103A1 (es) Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
BR0314844A (pt) Novo composto

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]